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Abstract Introduction Women require effective contraception until they reach menopause.
The long acting reversible contraceptives (LARC) and the depot-medroxyprogesterone
acetate (DMPA, Depo-Provera®, Pfizer, Puurs, Belgium) are great options and can
replace possible sterilizations.
Purpose To assess the relationship between the use of LARCs and DMPA and
terminations ascribed to menopause and sterilizations in a Brazilian clinic.
Methods We reviewed the records of women between 12 and 50 years of age
attending the clinic that chose to use a LARCmethod or DMPA. Cumulative termination
rates due to sterilization or because the woman had reached menopause were
computed using single decrement life-table analysis over 32 years. We also examined
all records of surgical sterilization at our hospital between the years 1980–2012.
Results Three hundred thirty-two women had continuously used the same contra-
ceptive until menopause, and 555 women had discontinued the method because they
or their partners underwent sterilization. From year 20 to year 30 of use, levonorgestrel
intrauterine-releasing system (LNG-IUS – Mirena®, Bayer Oy, Turku, Finland; available
since 1980), copper intrauterine device (IUD – available since 1980) and DMPA users
showed a trend of cumulative higher discontinuation rates due to menopause when
compared with the discontinuation rates due to sterilization. Over the study period, a
steep decline in the use of sterilization occurred.
received
January 1, 2016
accepted
March 16, 2016
published online
May 17, 2016
DOI http://dx.doi.org/
10.1055/s-0036-1583758.
ISSN 0100-7203.
Copyright © 2016 by Thieme Publicações
Ltda, Rio de Janeiro, Brazil
Original Article
THIEME
210
Introduction
Unintendedpregnancies represent amajor publichealth issue.
In developed countries, more than 40% of pregnancies occur-
ring each year are unintended.1 Despite the decline in fertility
with age, women require effective contraception until they
reachmenopause.2Worldwide, 61% of womenwith ages from
15 to 49 use some kind of contraception to avoid pregnancy;
however, a considerable proportion of unintended pregnan-
cies continues to occur due to incorrect use or premature
discontinuation of contraceptive methods.3
For womenwho find it difficult to use a contraceptive that
requires daily or periodic attention, long-acting reversible
contraceptives (LARCs; the copper intrauterine device [Cu-
IUD], the levonorgestrel-releasing intrauterine system [LNG-
IUS], levonorgestrel- [LNG – Norplant®, Bayer Oy, Turku,
Finland; available since between 1985 and August 2001] and
etonogestrel [ENG – Implanon®, Merck, Oss, Holland avail-
able since 2003] – releasing subdermal implants) and DMPA
represent a possible option due to their very low failure rates,
which are similar to those found with female sterilization.4
Many women need contraception during 28 to 30 years
of their lives and after the birth of their last child they still
need contraception for 15 years or more.5 Despite the
availability of many reversible contraceptives, female and
male sterilization remains a popular method worldwide.
Between 2003 and 2004 in the United Kingdom (UK),
around 25% of couples opted for female or male steriliza-
tion,6 while 37% of women in the United States (US) chose
sterilization.7 In Brazil, around 29% of women have opted
for sterilization.8
Female sterilization is associated with several risks, in-
cluding subsequent regret, unplanned and ectopic preg-
nancy, bowel and bladder injuries, complications related to
anesthesia, pain following the procedure and dyspareunia.9
Furthermore, life table analysis of 10-year cumulative failure
rates of sterilization methods range from 36.5 per 1,000
procedures for clip sterilization to 7.5 per 1,000 procedures
both for unipolar coagulation and for postpartum partial
salpingectomy,with ectopic pregnancyoccurring in 7.3 cases
per 1,000 procedures. With respect to vasectomy,
Conclusion Over the past 15 years of research we have observed a trend: women
usually preferred to continue using LARC methods or DMPA until menopause rather
than decide for sterilization, be it their own, or their partners’. The annual number of
sterilizations dropped in the same period. The use of LARC methods and DMPA until
menopause is an important option to avoid sterilization, which requires a surgical
procedure with potential complications.
Resumo Introdução Mulheres necessitam de contracepção até atingirem a menopausa. Os
contraceptivos reversíveis de longa duração e o acetato de medroxiprogesterona de
depósito (AMPD) são ótimas opções para substituir possíveis esterilizações.
Objetivo Avaliar a relação entre o uso de contraceptivos reversíveis de longa duração
(LARCs) e AMPD com terminações atribuídas à menopausa e a esterilizações em uma
clínica brasileira.
Métodos Revisamos os registros de mulheres entre 12 e 50 anos de idade atendidas
em clínica e que escolheram usar LARC ou AMPD. Índices de terminação acumulada
devido à esterilização ou à menopausa foram computados usando análise de tabela de
vida durante 32 anos. Também examinamos todos os registros de cirurgias de
esterilização em nosso hospital no período de 1980 a 2012.
Resultados Trezentas e trinta e duas mulheres usaram continuamente o mesmo
contraceptivo até a menopausa, e 555 mulheres não deram continuidade ao método
pelo fato de elas ou seus parceiros terem se submetido à esterilização. De 20 a 30 anos
de uso, usuários de sistema intrauterino de levonorgestrel, dispositivo intrauterino de
cobre e AMPD apresentaram tendência demaiores índices de descontinuidade devido à
menopausa quando comparados a índices de descontinuidade devido à esterilização.
No período de estudo, ocorreu um declínio acentuado no uso de esterilização.
Conclusão Nos últimos 15 anos do estudo, foi observada uma tendência na qual
mulheres optaram mais por continuar usando LARC ou AMPD até a menopausa do que
pela esterilização própria ou de seus parceiros. O número anual de esterilizações caiu
no mesmo período. O uso de LARC e AMPD até a menopausa é uma opção importante
para evitar a esterilização, que exige um procedimento cirúrgico com potenciais
complicações.
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postoperative hematoma, pain, infection and granuloma are
the most common complications.10
Due to the safety of LARC methods and DMPA, these
contraceptives are excellent options for women who have
completed their families and need contraception for many
more years until menopause.1,4,8 There is scarce information
on the uninterrupted long-term use of LARC methods or
DMPA until menopause and its relationship to the number of
female or male sterilizations. Consequently, the aim of this
study was to investigate this relationship in more detail and
to contrast the characteristics of the women who switch
from copper IUD, LNG-IUS, implants andDMPA to permanent
contraception with those of the women who continued to
use these reversible methods until menopause at a Brazilian
university-based clinic.
Methods
This was a study performed at the Family Planning Clinic,
Department of Obstetrics and Gynecology, Faculdade de
Ciências Médicas, Universidade Estadual de Campinas (Uni-
camp), Campinas, São Paulo, Brazil. The clinic was estab-
lished over 30 years ago. The Ethical Committee approved the
protocol. Informed consent was waived because the study
consisted of reviewing medical records and the data were
retrievedwithout identifying thewomen. Details of different
aspects of this study have been published previously.8
Population and Participants
Women of 12 to 50 years of age attending the clinicwere able
to freely choose whether they wanted to use copper IUD,
LNG-IUS, LNG-releasing implant, ENG-releasing implant,
DMPA or other contraceptive methods. For those women
who chose copper IUD, the device available from the begin-
ning of the study up to April 1988 was the TCu200B. After
that date and up to 2001, the device available was the
TCu380A (ParaGard®, Ortho Pharmaceutical, Don Mills, On-
tario, Canada). From 2001 onwards, the Optima® TCu380A-
IUD (which is identical in shape and copper surface to the
TCu380Amanufactured in theUS) (Injeflex, São Paulo, Brazil)
was the device available.
Taking into consideration the 50,004 medical charts
available at the clinic of women who had consulted for the
first time between January 2nd, 1980 and December 31st,
2012, we were able to obtain 16,115 medical charts of the
womenwho came to the clinic for a follow-up for at least one
year. We identified 20,821 segment of use of copper IUD,
LNG-IUS, implants and DMPA users (women who had these
contraceptives as first option or those who were using other
method and switched to one of the studied methods).
Women who received LNG-IUS exclusively for therapeutic
purposes were excluded from the study. The women who
adopted one of the methods and later switched to steriliza-
tion or reached menopause before the end of the first year of
follow-up were excluded from the analysis.
For data analysis, the number of years spent using the
method was considered continuous if a copper IUD, LNG-IUS
or implant user replaced the devicewith another on the same
day in which the previous device was removed, at the end of
its contraceptive life span. A previous publication from our
clinic8 reported on continuation and pregnancy rates. This
report presents data from the same cohorts regarding ter-
minations when women reached menopause or when the
women or their partners were sterilized. To evaluate use
untilmenopause, the termination datewas considered as the
last day of menstruation or, in the case of amenorrheic
women, the day of the second follicle-stimulating hormone
(FSH) measurement (the latter measured 90 days after the
former) with values > 40 mIU/mL.
Cumulative survival rates (for each method) and termina-
tion rates consequent to female or male sterilization or
because the woman had reached menopause were evaluated
using single decrement life-table analysis (with annual
intervals). Other terminations and failures to follow-up
were treated as censored cases. The Wilcoxon-Gehan test
was used to assess statistical significance of the differences
between rates.
Sociodemographic data of women who terminated for
these two reasons are presented as means  standard error
of the mean (SEM) or as percentage distributions for cate-
gorical variables. Life table data are presented in 5-year
intervals up to a total of 30 years of use; however, the total
evaluation period covered 32 years. Two sets of cumulative
termination rates attributed tomenopause or sterilization of
each contraceptive are presented as rates per 100 with their
standard errors (SEs). The SPSS statistical software program,
version 20 (Chicago, USA, 2012), was used. Significance was
established at p < 0.05.
Results
A chart review showed that 332 women had used a LARC
method or DMPA until menopause, and that 555 women had
discontinued because they or their partners had opted for
surgical sterilization at our hospital or returned to our clinic
for follow-up after a surgical procedure performed
elsewhere. ►Table 1 lists the women’s principal sociodemo-
graphic characteristics. The mean age  SEM of the women
at admission to the study was 37.0  0.36 years for women
who used the method until menopause, and 30.3  0.23
years (p < 0.001) for those who had discontinued due to
sterilization. The pattern of significantly younger age at
admission for the women, or their partners, whose fertility
ended with sterilization was observed in each decade. Ad-
ditionally, most of the women who underwent sterilization
had their first consultation at our clinic at the age of 34 or
less.
At admission, among those who used the method until
menopause, most reported between 1–4 years of schooling
(59.5%), whereas the largest group (46.6%) of women who
discontinued due to sterilization reported between 5–8
years of schooling.
►Table 2 shows the cumulative termination rates result-
ing from sterilization or from menopause and the contra-
ceptivemethod used uninterruptedly since thewoman’sfirst
visit to the clinic. The data are displayed in 5-year segments,
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Table 2 Cumulative discontinuation rates (with SEs) of LARC contraceptives and DMPA due to menopause or to male or female
surgical sterilization for each 5-year segment
Reason/
Periods of use (years)
Contraceptive method
Implant Copper IUD LNG-IUS DMPA
Menopause
5 0.0 (<glyph name¼"sbnd"/>) 0.2 (< 0.1) 0.7 (0.3) 1.8 (0.4)
10 0.0 (<glyph name¼"sbnd"/>) 1.5 (0.2) 7.6 (2.4) 9.6 (1.5)
15 3.1 (3.1) 6.6 (0.7) 13.7 (3.8) 25.3 (3.5)
20 12.1 (6.7) 17.7 (1.7) 31.7 (12.2) 57.3 (8.4)
25 12.1 (6.7) 43.7 (4.2) 31.7 (12.2) 69.5 (11.9)
Female or male sterilization
5 2.5 (1.2) 0.5 (0.1) 1.8 (0.5) 8.6 (0.7)
10 2.5 (1.2) 3.7 (0.3) 4.2 (1.5) 12.4 (1.1)
15 2.5 (1.2) 6.8 (0.5) 6.1 (2.4) 15.6 (1.8)
20 20.2 (9.3) 10.0 (1.0) 6.1 (2.4) 17.5 (2.6)
25 20.2 (9.3) 11.3 (1.6) 6.1 (2.4) 17.5 (2.6)
Abbreviations: Copper IUD, copper intrauterine device; DMPA, depot-medroxyprogesterone acetate; LARCs, long acting reversible contraceptives;
LNG-IUS, levonorgestrel intrauterine-releasing system.
Table 1 Baseline characteristics of the women using LARC contraceptives and DMPA until menopause or until undergoing
sterilization
Characteristics Women who continued
reversible contraceptive use
until menopause (n ¼ 332)
Women who opted for
surgical contraception
(n ¼ 555)
p-value
Age at admission (years)a Mean  SEM (range) n
37.0  0.36 (20–53)
Mean  SEM (range) n
30.3  0.23 (16–46)
p- value
< 0.001
Decade of 1980–1989b 32.2  5.4 (20–46) 123 26.3  4.2 (18–35) 50
Decade of 1990–1999b
Decade of 2000–2009a
Decade of 2010–2012b
38.5  5.2 (20–51) 156
43.1  4.9 (27–53) 49
40.1  8.7 (30–51) 4
29.4  5.1 (16–45) 244
31.9  5.4 (20–46) 247
31.0  4.6 (26–38) 14
Women over 30 years old at admission (%) 85.2 53.5 < 0.001
Women over 35 years old at admission (%) 62.6 22.0 < 0.001
Number of pregnancies n (%) n (%) 0.073#
0–2 156 (47.0) 219 (39.4)
3–4 129 (38.8) 234 (42.2)
 5 47 (14.2) 102 (18.4)
Years of schooling < 0.001#
Illiterate 22 (6.6) 24 (4.3)
1–4 193 (58.1) 170 (30.6)
5–8 77 (23.2) 258 (46.5)
9–12 29 (8.7) 91 (16.4)
> 12 11 (3.4) 12 (2.2)
Abbreviation: DMPA, depot-medroxyprogesterone acetate; LARCs, long acting reversible contraceptives; SEM, standard error of the mean.
Notes: aMean  SEM; bMean  standard deviation; t-test; #Pearson Chi-square.
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and the rates represent the “1-survival probability” (that is,
the termination probability of the specified decrement;
menopause or sterilization).
►Fig. 1 shows the cumulative termination (1-survival)
rates for the women who stopped due to menopause (Panel
A) and for the group who terminated because of sterilization
(Panel B). Except for implant users, most of the women who
stopped contraceptive use due to menopause consulted for
contraception for the first time at our clinic at 35 years old or
older. In our hospital, changes occurred in the number of
cases of female sterilization (not related to any obstetrics
event) performed over the study period. We recorded an
average of 216 procedures per year between 1980–1984; 218
between 1985–1989; 130 between 1990–1994; 146
Fig. 1 Cumulative discontinuation rates of LARC methods and DMPA due to menopause (Panel A) and due to female or male sterilization
(Panel B).
Abbreviations: DMPA, depot-medroxyprogesterone acetate; IUD, intrauterine device; LARCs, long acting reversible contraceptives; LNG-IUS,
levonorgestrel intrauterine-releasing system.
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between 1995–1999; 60 between 2000–2004; and 42 per
year between 2005–2009. The rates kept declining over the
last years.
Furthermore, we examined the heterogeneity among the
four methods in the termination rates separately for meno-
pause and for sterilization, andwe rejected the homogeneity
of the four samples both in general and at 5, 10, 15, and
20 years of observation due to the low number of cases
observed in some of the years. Among those who gave
menopause as a reason, the LNG-IUS group was significantly
different when compared to the IUD group; and the DMPA
group was significantly different from both IUD and implant
groups. However, considering the participants who gave
sterilization as a reason, the DMPA group differed signifi-
cantly from the other three groups.
Discussion
Female or male sterilization are the most common contra-
ceptivemethods usedworldwide, and are the choice ofmany
couples who have completed their families and seek contra-
ception until menopause despite the existence of several
surgical complications.11–13 The LARC methods and DMPA
are safe and practical alternatives to surgical sterilization.14
In the present study, there was a period of observation
whenmorewomen discontinued the use of LARCmethods or
DMPA because they or their partners chose sterilization
rather than waiting for the onset of menopause. Probably,
one important reason for choosing sterilization at that time
was because women did not know about the reversible
contraceptive options available, and were unaware that the
contraceptive effectiveness of LARC methods is similar to
that of female sterilization.4,8,15 Furthermore, at that time in
Brazil, tubal ligation became commonplace because of the
lack of LARC methods in both public and private sectors.11
Additionally, the women who opted for sterilization were
younger at the time of admission (mean of 30 years old or under
30 according to the decade of admission, in comparison to a
meanof37years oldamong thosewhocontinued touse LARCor
DMPA until menopause). In fact, except for the few implant
users, between 51 and 87% of the women who reached meno-
pause while using LARC methods were 35 or older at their first
consultation. In contrast, the groups that later opted for ster-
ilization contained between 62 to 94% of women who were
under 35 when they chose a LARC method or DMPA. It may be
legitimate to speculate that theyoungestwomenprobablyopted
for sterilization because they still had many fertile years. One
may judge that, also fromDMPA’s high overall termination rates
in the first 20 years of period, women reacted against DMPA’s
repeated inconveniences and side effects.
Life table rates of termination due to menopause were
high after 15–20 years of follow-up; however, because the
proportion of women who continued long-term contracep-
tive use was of the order of 20–25%, consequently the
numbers of women who terminated at a late date are small.
The termination rate for menopause in comparison to ter-
mination due to sterilization was not significantly higher for
the copper IUD, LNG-IUS and DMPA users.
As was previously shown, the number of sterilizations
declined over the years in our hospital. Thismay be one of the
explanations for the increase in the final years of the present
evaluation of the number of women using LARCmethods and
DMPA until menopause. We speculate that LARC and DMPA
users showed relatively high discontinuation rates due to
menopause because they were appropriately counselled
about the high effectiveness of these methods. DMPA users
received the injections at the clinic, which means that they
were perfect users,8,15 even though they had the inconve-
nience of having to return to the clinic for re-injections.
It is important to observe that the cumulative rate of
DMPA termination due to menopause was of 69.5/100 wo-
men, which is 4 times the cumulative termination rate for
sterilization (17.5/100women). The cumulative difference in
rates for later years grows favoring high levels of disconti-
nuation due to menopause. However, the total number of
women who reached menopause (83) after using DMPAwas
smaller than the number of those who discontinued DMPA
use due to sterilization (220). Furthermore, the outcomes
were influenced by the fact that the mean number of years
from acceptance to sterilization is lower than mean number
of years from acceptance to menopause.
The low continuation rates of DMPA contribute to the fact
that at every displayed evaluation points past initiation of
use, there was significantly higher rates of discontinuation
for menopause than among the users of IUD and LNG-IUS.
This adds to the fact that terminations due to sterilization by
DMPA users were significantly higher at the end of years 5,
10, 15 and 20 when compared with those of IUD users, and
were significantly higher at the end of years 5, 10 and 15
when compared with LNG-IUS users. The last observed
termination of DMPA for sterilization was in the 17th year
of use.
LARC or DMPA users came to the clinic at an older age
probably because they had fewer years of schooling andwere
less aware of the range of modern contraceptives. This is in
agreement with a previous study, which suggested that
health professionals actively encourage women to use
LARC methods instead of performing sterilization.16 In a
US-based study,17 120 Latino women, who had requested
sterilization and had been unable to obtain the procedure,
were interviewed to assess their knowledge of and interest in
using a LARC method. Overall, 51, 47 and 23% of the women
reported that they had heard about copper IUD, the implant
and LNG-IUS respectively; and 24% of the women stated that
they would use copper IUD, 14% would use LNG-IUS, and 9%
would use the implant. The main reasons given by the
women for not considering LARCmethods as a contraceptive
were concerns about side effects and the effectiveness of the
methods.
Another fact that needs to be taken into consideration is
that the decline in the number of sterilizations could be
linked to thewide use of emergency contraception or the use
of misoprostol (Cytotec®, Illertissen, Germany) to perform
medical abortions. Although in Brazil abortion is legal only in
restricted indications (rape, malformed fetus incompatible
with the extra uterine life or a life-threatening condition to
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the mother), the practice of abortion with misoprostol is
widely spread.18
In the US, the main contraceptives chosen by couples in
their final reproductive years still include female and male
sterilization.17,19–22 On the other hand, studies2,23 have
reported a decrease in the number of female sterilizations
and hysterectomies in Finland and in the UK over recent
years. The number of female sterilizations fell (55%) be-
tween 1996 and 2004, a period in which LNG-IUS sales
increased by 30% (from  22,000 to 29,000), although the
number of male sterilizations remained stable.
Probably many women may choose LNG-IUS instead of
undergoing surgical sterilization because this method not
only provides contraception but also controls heavy men-
strual bleeding (HMB), a common occurrence during meno-
pausal transition.24 Among women over 40 years of age,
between 33 and 50% present complaints of abnormal bleed-
ing or HMB.24 Consequently, the that both LNG-IUS and
DMPA reduce menstrual flow may have been one of the
factors that encouragedwomen to keep using thesemethods
until menopause. Sterilization does not improve menstrual
patterns, which tend to be irregular during thefinal years of a
woman’s reproductive life.
Long-term users of any contraceptive method are those
women who have fewer or no side effects with the method.
Side effects can influence the decision to switch from rever-
sible contraceptives to surgical sterilization. Women who
have any medical condition which was affected by the use of
contraceptives were probably those who opted for steriliza-
tion; however, women with serious medical conditions
might be poor surgical candidates and preferentially choose
LARC methods. Nevertheless, there is a new argument in
favor of female sterilization (salpingectomy); this procedure
apparently is able to prevent ovarian cancer because it could
avoid serous tubal intraepithelial carcinomas.25–27
The main strength of this study is the assessment of the
relationship between the large number of women who used
a LARC method or DMPA uninterruptedly until menopause
and those who terminated the method to adopt female or
male sterilization. The main limitation was the number of
womenwho never returned to the clinic, which introduces a
bias, because many of them could have been sterilized in
other facilities, or many could have used these contraceptive
methods until menopause without reporting it to us.
Furthermore, the low number of women who chose an
implant as a contraceptive method limits the analysis con-
cerning this contraceptive. Additionally, the women who
opted for the use of LARC methods until menopause were
significantly older at admission than those who opted for
surgical sterilization, andhad a significantly lower number of
years of schooling.
This study may provide valuable information for health
care professionals (HCP) and policy makers to promote the
use of these methods as a means of avoiding surgeries. One
may tell HCPs that they can recommend LARC methods to
thosewomenwho seek long-term contraception andwant to
avoid sterilization. It is important to conduct a prospective
study to assess the real trend in one direction to reduce
sterilizations and to increase the use of LARC methods and
DMPA. In addition, we were unable to assess the effect upon
discontinuation rates of thewomenwho switched fromLNG-
IUS to copper IUD and vice versa, or from DMPA to intrau-
terine contraceptive. In conclusion, in the past 15 years of
observation, the rates of womenwho opted to continue using
LARC methods or DMPA until menopause were higher than
those of women who opted for female or male sterilization.
The annual number of sterilizations dropped markedly dur-
ing the same period. This exploratory study showed that if
the women who used LARC methods and DMPA were satis-
fied in the long-term, they could continue the contraceptive
use until menopause and probably reduce the rates of
discontinuation due to sterilization.
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